Copyright Reports & Markets. All rights reserved.

COVID-19 Impact on Global Gefitinib Market Insights, Forecast to 2026

Request for Sample of this report
Buy now

1 Study Coverage

  • 1.1 Gefitinib Product Introduction
  • 1.2 Market Segments
  • 1.3 Key Gefitinib Manufacturers Covered: Ranking by Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Gefitinib Market Size Growth Rate by Type
    • 1.4.2 10 Tables/Box
    • 1.4.3 30 Tables/Box
    • 1.4.4 90 Tables/Box
  • 1.5 Market by Application
    • 1.5.1 Global Gefitinib Market Size Growth Rate by Application
    • 1.5.2 Hospital
    • 1.5.3 Clinic
    • 1.5.4 Drug Center
    • 1.5.5 Other
  • 1.6 Coronavirus Disease 2019 (Covid-19): Gefitinib Industry Impact
    • 1.6.1 How the Covid-19 is Affecting the Gefitinib Industry
      • 1.6.1.1 Gefitinib Business Impact Assessment - Covid-19
      • 1.6.1.2 Supply Chain Challenges
      • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
    • 1.6.2 Market Trends and Gefitinib Potential Opportunities in the COVID-19 Landscape
    • 1.6.3 Measures / Proposal against Covid-19
      • 1.6.3.1 Government Measures to Combat Covid-19 Impact
      • 1.6.3.2 Proposal for Gefitinib Players to Combat Covid-19 Impact
  • 1.7 Study Objectives
  • 1.8 Years Considered

2 Executive Summary

  • 2.1 Global Gefitinib Market Size Estimates and Forecasts
    • 2.1.1 Global Gefitinib Revenue 2015-2026
    • 2.1.2 Global Gefitinib Sales 2015-2026
  • 2.2 Gefitinib Market Size by Region: 2020 Versus 2026
    • 2.2.1 Global Gefitinib Retrospective Market Scenario in Sales by Region: 2015-2020
    • 2.2.2 Global Gefitinib Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Gefitinib Competitor Landscape by Players

  • 3.1 Gefitinib Sales by Manufacturers
    • 3.1.1 Gefitinib Sales by Manufacturers (2015-2020)
    • 3.1.2 Gefitinib Sales Market Share by Manufacturers (2015-2020)
  • 3.2 Gefitinib Revenue by Manufacturers
    • 3.2.1 Gefitinib Revenue by Manufacturers (2015-2020)
    • 3.2.2 Gefitinib Revenue Share by Manufacturers (2015-2020)
    • 3.2.3 Global Gefitinib Market Concentration Ratio (CR5 and HHI) (2015-2020)
    • 3.2.4 Global Top 10 and Top 5 Companies by Gefitinib Revenue in 2019
    • 3.2.5 Global Gefitinib Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Gefitinib Price by Manufacturers
  • 3.4 Gefitinib Manufacturing Base Distribution, Product Types
    • 3.4.1 Gefitinib Manufacturers Manufacturing Base Distribution, Headquarters
    • 3.4.2 Manufacturers Gefitinib Product Type
    • 3.4.3 Date of International Manufacturers Enter into Gefitinib Market
  • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

  • 4.1 Global Gefitinib Market Size by Type (2015-2020)
    • 4.1.1 Global Gefitinib Sales by Type (2015-2020)
    • 4.1.2 Global Gefitinib Revenue by Type (2015-2020)
    • 4.1.3 Gefitinib Average Selling Price (ASP) by Type (2015-2026)
  • 4.2 Global Gefitinib Market Size Forecast by Type (2021-2026)
    • 4.2.1 Global Gefitinib Sales Forecast by Type (2021-2026)
    • 4.2.2 Global Gefitinib Revenue Forecast by Type (2021-2026)
    • 4.2.3 Gefitinib Average Selling Price (ASP) Forecast by Type (2021-2026)
  • 4.3 Global Gefitinib Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Breakdown Data by Application (2015-2026)

  • 5.1 Global Gefitinib Market Size by Application (2015-2020)
    • 5.1.1 Global Gefitinib Sales by Application (2015-2020)
    • 5.1.2 Global Gefitinib Revenue by Application (2015-2020)
    • 5.1.3 Gefitinib Price by Application (2015-2020)
  • 5.2 Gefitinib Market Size Forecast by Application (2021-2026)
    • 5.2.1 Global Gefitinib Sales Forecast by Application (2021-2026)
    • 5.2.2 Global Gefitinib Revenue Forecast by Application (2021-2026)
    • 5.2.3 Global Gefitinib Price Forecast by Application (2021-2026)

6 North America

  • 6.1 North America Gefitinib by Country
    • 6.1.1 North America Gefitinib Sales by Country
    • 6.1.2 North America Gefitinib Revenue by Country
    • 6.1.3 U.S.
    • 6.1.4 Canada
  • 6.2 North America Gefitinib Market Facts & Figures by Type
  • 6.3 North America Gefitinib Market Facts & Figures by Application

7 Europe

  • 7.1 Europe Gefitinib by Country
    • 7.1.1 Europe Gefitinib Sales by Country
    • 7.1.2 Europe Gefitinib Revenue by Country
    • 7.1.3 Germany
    • 7.1.4 France
    • 7.1.5 U.K.
    • 7.1.6 Italy
    • 7.1.7 Russia
  • 7.2 Europe Gefitinib Market Facts & Figures by Type
  • 7.3 Europe Gefitinib Market Facts & Figures by Application

8 Asia Pacific

  • 8.1 Asia Pacific Gefitinib by Region
    • 8.1.1 Asia Pacific Gefitinib Sales by Region
    • 8.1.2 Asia Pacific Gefitinib Revenue by Region
    • 8.1.3 China
    • 8.1.4 Japan
    • 8.1.5 South Korea
    • 8.1.6 India
    • 8.1.7 Australia
    • 8.1.8 Taiwan
    • 8.1.9 Indonesia
    • 8.1.10 Thailand
    • 8.1.11 Malaysia
    • 8.1.12 Philippines
    • 8.1.13 Vietnam
  • 8.2 Asia Pacific Gefitinib Market Facts & Figures by Type
  • 8.3 Asia Pacific Gefitinib Market Facts & Figures by Application

9 Latin America

  • 9.1 Latin America Gefitinib by Country
    • 9.1.1 Latin America Gefitinib Sales by Country
    • 9.1.2 Latin America Gefitinib Revenue by Country
    • 9.1.3 Mexico
    • 9.1.4 Brazil
    • 9.1.5 Argentina
  • 9.2 Central & South America Gefitinib Market Facts & Figures by Type
  • 9.3 Central & South America Gefitinib Market Facts & Figures by Application

10 Middle East and Africa

  • 10.1 Middle East and Africa Gefitinib by Country
    • 10.1.1 Middle East and Africa Gefitinib Sales by Country
    • 10.1.2 Middle East and Africa Gefitinib Revenue by Country
    • 10.1.3 Turkey
    • 10.1.4 Saudi Arabia
    • 10.1.5 U.A.E
  • 10.2 Middle East and Africa Gefitinib Market Facts & Figures by Type
  • 10.3 Middle East and Africa Gefitinib Market Facts & Figures by Application

11 Company Profiles

  • 11.1 AstraZeneca
    • 11.1.1 AstraZeneca Corporation Information
    • 11.1.2 AstraZeneca Description, Business Overview and Total Revenue
    • 11.1.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 AstraZeneca Gefitinib Products Offered
    • 11.1.5 AstraZeneca Recent Development
  • 11.2 Qilu Pharmaceutical
    • 11.2.1 Qilu Pharmaceutical Corporation Information
    • 11.2.2 Qilu Pharmaceutical Description, Business Overview and Total Revenue
    • 11.2.3 Qilu Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
    • 11.2.4 Qilu Pharmaceutical Gefitinib Products Offered
    • 11.2.5 Qilu Pharmaceutical Recent Development
  • 11.3 Natco Pharma
    • 11.3.1 Natco Pharma Corporation Information
    • 11.3.2 Natco Pharma Description, Business Overview and Total Revenue
    • 11.3.3 Natco Pharma Sales, Revenue and Gross Margin (2015-2020)
    • 11.3.4 Natco Pharma Gefitinib Products Offered
    • 11.3.5 Natco Pharma Recent Development
  • 11.4 Celon Laboratories
    • 11.4.1 Celon Laboratories Corporation Information
    • 11.4.2 Celon Laboratories Description, Business Overview and Total Revenue
    • 11.4.3 Celon Laboratories Sales, Revenue and Gross Margin (2015-2020)
    • 11.4.4 Celon Laboratories Gefitinib Products Offered
    • 11.4.5 Celon Laboratories Recent Development
  • 11.5 Hetero Drugs
    • 11.5.1 Hetero Drugs Corporation Information
    • 11.5.2 Hetero Drugs Description, Business Overview and Total Revenue
    • 11.5.3 Hetero Drugs Sales, Revenue and Gross Margin (2015-2020)
    • 11.5.4 Hetero Drugs Gefitinib Products Offered
    • 11.5.5 Hetero Drugs Recent Development
  • 11.6 Dr Reddy's Laboratories
    • 11.6.1 Dr Reddy's Laboratories Corporation Information
    • 11.6.2 Dr Reddy's Laboratories Description, Business Overview and Total Revenue
    • 11.6.3 Dr Reddy's Laboratories Sales, Revenue and Gross Margin (2015-2020)
    • 11.6.4 Dr Reddy's Laboratories Gefitinib Products Offered
    • 11.6.5 Dr Reddy's Laboratories Recent Development
  • 11.7 Zuventus Healthcare
    • 11.7.1 Zuventus Healthcare Corporation Information
    • 11.7.2 Zuventus Healthcare Description, Business Overview and Total Revenue
    • 11.7.3 Zuventus Healthcare Sales, Revenue and Gross Margin (2015-2020)
    • 11.7.4 Zuventus Healthcare Gefitinib Products Offered
    • 11.7.5 Zuventus Healthcare Recent Development
  • 11.8 United Biotech
    • 11.8.1 United Biotech Corporation Information
    • 11.8.2 United Biotech Description, Business Overview and Total Revenue
    • 11.8.3 United Biotech Sales, Revenue and Gross Margin (2015-2020)
    • 11.8.4 United Biotech Gefitinib Products Offered
    • 11.8.5 United Biotech Recent Development
  • 11.9 Panacea Biotec
    • 11.9.1 Panacea Biotec Corporation Information
    • 11.9.2 Panacea Biotec Description, Business Overview and Total Revenue
    • 11.9.3 Panacea Biotec Sales, Revenue and Gross Margin (2015-2020)
    • 11.9.4 Panacea Biotec Gefitinib Products Offered
    • 11.9.5 Panacea Biotec Recent Development
  • 11.10 Cipla
    • 11.10.1 Cipla Corporation Information
    • 11.10.2 Cipla Description, Business Overview and Total Revenue
    • 11.10.3 Cipla Sales, Revenue and Gross Margin (2015-2020)
    • 11.10.4 Cipla Gefitinib Products Offered
    • 11.10.5 Cipla Recent Development
  • 11.1 AstraZeneca
    • 11.1.1 AstraZeneca Corporation Information
    • 11.1.2 AstraZeneca Description, Business Overview and Total Revenue
    • 11.1.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 AstraZeneca Gefitinib Products Offered
    • 11.1.5 AstraZeneca Recent Development
  • 11.12 Nobel Ilac Sanayii Ve Ticaret
    • 11.12.1 Nobel Ilac Sanayii Ve Ticaret Corporation Information
    • 11.12.2 Nobel Ilac Sanayii Ve Ticaret Description, Business Overview and Total Revenue
    • 11.12.3 Nobel Ilac Sanayii Ve Ticaret Sales, Revenue and Gross Margin (2015-2020)
    • 11.12.4 Nobel Ilac Sanayii Ve Ticaret Products Offered
    • 11.12.5 Nobel Ilac Sanayii Ve Ticaret Recent Development
  • 11.13 Accure Labs
    • 11.13.1 Accure Labs Corporation Information
    • 11.13.2 Accure Labs Description, Business Overview and Total Revenue
    • 11.13.3 Accure Labs Sales, Revenue and Gross Margin (2015-2020)
    • 11.13.4 Accure Labs Products Offered
    • 11.13.5 Accure Labs Recent Development
  • 11.14 Cadila Pharmaceuticals
    • 11.14.1 Cadila Pharmaceuticals Corporation Information
    • 11.14.2 Cadila Pharmaceuticals Description, Business Overview and Total Revenue
    • 11.14.3 Cadila Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
    • 11.14.4 Cadila Pharmaceuticals Products Offered
    • 11.14.5 Cadila Pharmaceuticals Recent Development
  • 11.15 Ethypharm
    • 11.15.1 Ethypharm Corporation Information
    • 11.15.2 Ethypharm Description, Business Overview and Total Revenue
    • 11.15.3 Ethypharm Sales, Revenue and Gross Margin (2015-2020)
    • 11.15.4 Ethypharm Products Offered
    • 11.15.5 Ethypharm Recent Development
  • 11.16 Flagship Biotech International
    • 11.16.1 Flagship Biotech International Corporation Information
    • 11.16.2 Flagship Biotech International Description, Business Overview and Total Revenue
    • 11.16.3 Flagship Biotech International Sales, Revenue and Gross Margin (2015-2020)
    • 11.16.4 Flagship Biotech International Products Offered
    • 11.16.5 Flagship Biotech International Recent Development
  • 11.17 Globela Pharma
    • 11.17.1 Globela Pharma Corporation Information
    • 11.17.2 Globela Pharma Description, Business Overview and Total Revenue
    • 11.17.3 Globela Pharma Sales, Revenue and Gross Margin (2015-2020)
    • 11.17.4 Globela Pharma Products Offered
    • 11.17.5 Globela Pharma Recent Development
  • 11.18 Jodas Expoim
    • 11.18.1 Jodas Expoim Corporation Information
    • 11.18.2 Jodas Expoim Description, Business Overview and Total Revenue
    • 11.18.3 Jodas Expoim Sales, Revenue and Gross Margin (2015-2020)
    • 11.18.4 Jodas Expoim Products Offered
    • 11.18.5 Jodas Expoim Recent Development
  • 11.19 Nishchay Pharmaceuticals
    • 11.19.1 Nishchay Pharmaceuticals Corporation Information
    • 11.19.2 Nishchay Pharmaceuticals Description, Business Overview and Total Revenue
    • 11.19.3 Nishchay Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
    • 11.19.4 Nishchay Pharmaceuticals Products Offered
    • 11.19.5 Nishchay Pharmaceuticals Recent Development
  • 11.20 Sichuan Xieli Pharmaceutical
    • 11.20.1 Sichuan Xieli Pharmaceutical Corporation Information
    • 11.20.2 Sichuan Xieli Pharmaceutical Description, Business Overview and Total Revenue
    • 11.20.3 Sichuan Xieli Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
    • 11.20.4 Sichuan Xieli Pharmaceutical Products Offered
    • 11.20.5 Sichuan Xieli Pharmaceutical Recent Development

12 Future Forecast by Regions (Countries) (2021-2026)

  • 12.1 Gefitinib Market Estimates and Projections by Region
    • 12.1.1 Global Gefitinib Sales Forecast by Regions 2021-2026
    • 12.1.2 Global Gefitinib Revenue Forecast by Regions 2021-2026
  • 12.2 North America Gefitinib Market Size Forecast (2021-2026)
    • 12.2.1 North America: Gefitinib Sales Forecast (2021-2026)
    • 12.2.2 North America: Gefitinib Revenue Forecast (2021-2026)
    • 12.2.3 North America: Gefitinib Market Size Forecast by Country (2021-2026)
  • 12.3 Europe Gefitinib Market Size Forecast (2021-2026)
    • 12.3.1 Europe: Gefitinib Sales Forecast (2021-2026)
    • 12.3.2 Europe: Gefitinib Revenue Forecast (2021-2026)
    • 12.3.3 Europe: Gefitinib Market Size Forecast by Country (2021-2026)
  • 12.4 Asia Pacific Gefitinib Market Size Forecast (2021-2026)
    • 12.4.1 Asia Pacific: Gefitinib Sales Forecast (2021-2026)
    • 12.4.2 Asia Pacific: Gefitinib Revenue Forecast (2021-2026)
    • 12.4.3 Asia Pacific: Gefitinib Market Size Forecast by Region (2021-2026)
  • 12.5 Latin America Gefitinib Market Size Forecast (2021-2026)
    • 12.5.1 Latin America: Gefitinib Sales Forecast (2021-2026)
    • 12.5.2 Latin America: Gefitinib Revenue Forecast (2021-2026)
    • 12.5.3 Latin America: Gefitinib Market Size Forecast by Country (2021-2026)
  • 12.6 Middle East and Africa Gefitinib Market Size Forecast (2021-2026)
    • 12.6.1 Middle East and Africa: Gefitinib Sales Forecast (2021-2026)
    • 12.6.2 Middle East and Africa: Gefitinib Revenue Forecast (2021-2026)
    • 12.6.3 Middle East and Africa: Gefitinib Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

  • 13.1 Market Opportunities and Drivers
  • 13.2 Market Challenges
  • 13.3 Market Risks/Restraints
  • 13.4 Porter’s Five Forces Analysis
  • 13.5 Primary Interviews with Key Gefitinib Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

  • 14.1 Value Chain Analysis
  • 14.2 Gefitinib Customers
  • 14.3 Sales Channels Analysis
    • 14.3.1 Sales Channels
    • 14.3.2 Distributors

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Research Methodology
      • 16.1.1 Methodology/Research Approach
      • 16.1.2 Data Source

    Gefitinib market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Gefitinib market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

    Segment by Type, the Gefitinib market is segmented into
    10 Tables/Box
    30 Tables/Box
    90 Tables/Box

    Segment by Application, the Gefitinib market is segmented into
    Hospital
    Clinic
    Drug Center
    Other

    Regional and Country-level Analysis
    The Gefitinib market is analysed and market size information is provided by regions (countries).
    The key regions covered in the Gefitinib market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
    The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
    Competitive Landscape and Gefitinib Market Share Analysis
    Gefitinib market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Gefitinib business, the date to enter into the Gefitinib market, Gefitinib product introduction, recent developments, etc.
    The major vendors covered:
    AstraZeneca
    Qilu Pharmaceutical
    Natco Pharma
    Celon Laboratories
    Hetero Drugs
    Dr Reddy's Laboratories
    Zuventus Healthcare
    United Biotech
    Panacea Biotec
    Cipla
    Glenmark Pharmaceuticals
    Nobel Ilac Sanayii Ve Ticaret
    Accure Labs
    Cadila Pharmaceuticals
    Ethypharm
    Flagship Biotech International
    Globela Pharma
    Jodas Expoim
    Nishchay Pharmaceuticals
    Sichuan Xieli Pharmaceutical

    Buy now